Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study

Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study

Abstract Background To date, there is no approved blood‐based biomarker for breast cancer detection. Herein, we aimed to assess semaphorin 4C (SEMA4C), a pivotal protein involved in breast cancer progression, as a serum diagnostic biomarker. Methods We included 6,213 consecutive inpatients from Tong...

Full description

Bibliographic Details
Main Authors: Ya Wang, Long Qiao, Jie Yang, Xiong Li, Yaqi Duan, Jiahao Liu, Shaoqi Chen, Huayi Li, Dan Liu, Tian Fang, Jingjing Ma, Xiaoting Li, Fei Ye, Junxiang Wan, Juncheng Wei, Qin Xu, Ensong Guo, Ping Jin, Mingfu Wu, Lin Zhang, Yun Xia, Yaqun Wu, Jun Shao, Yaojun Feng, Qing Zhang, Zongyuan Yang, Gang Chen, Qinghua Zhang, Xingrui Li, Shixuan Wang, Junbo Hu, Xiaoyun Wang, Mona P. Tan, Kazuaki Takabe, Beihua Kong, Qifeng Yang, Ding Ma, Qinglei Gao
Format: Article
Language:English
Published: Wiley 2021-12-01
Series:Cancer Communications
Subjects:
breast cancer
semaphorin 4C
serum biomarker
diagnosis
early detection
ductal carcinoma in situ
Online Access:https://doi.org/10.1002/cac2.12233

Internet

https://doi.org/10.1002/cac2.12233

Similar Items